TAKE Solutions Board Approves Name Change, Auditor Appointment, and MOA Amendments at May 13 Meeting

3 min read     Updated on 13 May 2026, 07:41 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

TAKE Solutions Limited's board, at its May 13, 2026 meeting, approved a name change to TAKE Limited subject to MCA and member approvals, and appointed M/s. A. Raghavendra Rao & Associates as Statutory Auditors to fill a casual vacancy. The board also approved amendments to the Memorandum of Association to align with the Companies Act, 2013 and to expand business objects into healthcare technology, digital health, diagnostics, pharmaceuticals, biotechnology, and clinical research. A Postal Ballot process has been initiated, with e-voting open from May 18, 2026, to June 16, 2026, and M/s. Hemang Satra & Associates appointed as Scrutinizer.

powered bylight_fuzz_icon
40227062

*this image is generated using AI for illustrative purposes only.

The Board of Directors of TAKE Solutions Limited held a meeting on Wednesday, May 13, 2026, approving a series of significant corporate actions pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 03:00 PM and concluded at 04:00 PM. The decisions encompass a proposed company name change, a new statutory auditor appointment, amendments to the Memorandum of Association, and the initiation of a Postal Ballot process for member approval.

Key Decisions at a Glance

The board approved multiple resolutions spanning corporate identity, governance, and business expansion. The following table summarises the major decisions taken at the meeting:

Decision: Details
Name Change: From "TAKE SOLUTIONS LIMITED" to "TAKE LIMITED", subject to MCA approval and member/regulatory consent
Statutory Auditor Appointment: M/s. A. Raghavendra Rao & Associates, Chartered Accountants (FRN: 003324S, PRC No.: 018363) to fill casual vacancy
MOA Revision: Adoption of new MOA aligned with Companies Act, 2013; merger of Clause III(C) into Clause III(B)
MOA Object Clause Amendment: Insertion of new object clauses under Clause III(A) and III(B)
Postal Ballot Scrutinizer: M/s. Hemang Satra & Associates, Practicing Company Secretaries (COP: 24235, PRC: 5684/2024)

Proposed Name Change

The board approved a proposal to change the company's name from "TAKE SOLUTIONS LIMITED" to "TAKE LIMITED". This change is contingent upon receipt of approval from the Ministry of Corporate Affairs regarding name availability under Section 4(5) of the Companies Act, 2013, and is further subject to the approval of members as well as any other requisite regulatory or statutory authorities.

Statutory Auditor Appointment

The board approved the appointment of M/s. A. Raghavendra Rao & Associates, Chartered Accountants, bearing Firm Registration Number 003324S and Peer Review Certificate Number 018363, as Statutory Auditors of the company. This appointment has been made to fill a casual vacancy in the auditor position.

Memorandum of Association Amendments

Two distinct amendments to the Memorandum of Association were approved at the meeting, reflecting both a compliance update and a strategic business expansion.

Alignment with Companies Act, 2013

The existing MOA of the company was framed under the provisions of the Companies Act, 1956 and currently contains Clause III(C) relating to "Other Objects." Since the Companies Act, 2013 no longer requires the concept of "Other Objects," the board approved the adoption of a revised MOA. The revision involves merging the existing Clause III(C) into Clause III(B), which pertains to Objects Incidental or Ancillary to the attainment of the Main Objects, with the clauses to be renumbered accordingly. The existing objects of the company remain unaffected by this restructuring.

Expansion of Business Objects

To enable the company to undertake new business activities, the board approved the insertion of additional clauses under both Clause III(A) – Main Objects and Clause III(B) – Objects Incidental or Ancillary to the attainment of the Main Objects. The proposed amendment enables the company to undertake business activities in the following areas:

  • Healthcare technology
  • Digital health solutions
  • Diagnostics
  • Pharmaceuticals
  • Biotechnology
  • Clinical research
  • Allied sectors

Postal Ballot Process

The board approved the initiation of a Postal Ballot process to obtain member approval for the above resolutions through Postal Ballot forms and remote e-voting. M/s. Hemang Satra & Associates, Practicing Company Secretaries (COP: 24235 and PRC: 5684/2024), have been appointed as the Scrutinizer for the proposed Postal Ballot. The key dates for the process are as follows:

Parameter: Details
Cut-off Date for E-Voting: Friday, May 08, 2026
E-Voting Commencement: Monday, May 18, 2026 (from 9:00 AM)
E-Voting Conclusion: Tuesday, June 16, 2026 (till 5:00 PM)

The disclosures have been made in accordance with Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The communication was signed by Director Parmeshvar Dhangare (DIN: 11410125) on behalf of the company.

Historical Stock Returns for Take Solutions

1 Day5 Days1 Month6 Months1 Year5 Years
-4.97%-26.43%-41.90%-1.89%+234.66%-55.98%

How might TAKE Solutions' expansion into healthcare technology, pharmaceuticals, and biotechnology impact its revenue mix and competitive positioning against established players in these sectors over the next 2-3 years?

What strategic acquisitions or partnerships could TAKE Limited pursue to accelerate its entry into clinical research and digital health solutions following the MOA amendments?

How will the casual vacancy in the statutory auditor position and the appointment of a new auditor potentially affect investor confidence and the company's upcoming financial disclosures?

Take Solutions Limited announces strategic entry into longevity market under Reg 30

2 min read     Updated on 23 Apr 2026, 08:24 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Take Solutions Limited has formally announced its strategic expansion into India's longevity and anti-aging market through a Regulation 30 filing. The company plans to leverage its healthcare expertise to develop science-backed nutraceuticals, biohacking solutions, and digital health tools, targeting a global market valued at USD 27.61 billion in 2025 and projected to reach USD 67.03 billion by 2035.

powered bylight_fuzz_icon
37948685

*this image is generated using AI for illustrative purposes only.

Take Solutions Limited has announced its strategic entry into India's longevity and anti-aging market through a comprehensive Regulation 30 filing dated April 17, 2026, marking a significant expansion into the healthcare and wellness sector.

Regulatory Filing Details

The company submitted formal notifications to both BSE Limited and National Stock Exchange of India Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing outlined plans to disrupt the Indian longevity and anti-aging solutions market through science-backed nutraceuticals, biohacking solutions, and technology-enabled preventive healthcare offerings.

Parameter: Details
Filing Date: April 17, 2026
BSE Script Code: 532890
NSE Scrip: TAKE
Regulation: SEBI Reg 30 (LODR) 2015
Focus Areas: Nutraceuticals, Biohacking, Digital Health

Market Opportunity and Growth Projections

The global longevity market presents substantial growth opportunities across multiple segments. The company aims to capitalize on India's growing health-conscious consumer base through its established expertise in clinical research and regulatory processes.

Market Segment: 2025 Value Future Projection CAGR
Global Longevity Market: USD 27.61 billion USD 67.03 billion (2035) 9.41%
India Anti-aging Supplements: USD 168.60 million USD 341.40 million (2033) 9.50%
India Anti-aging Services: USD 567.50 million (2024) USD 1,059.60 million (2035) 5.80%
India Preventive Healthcare: USD 197.00 billion - -

Strategic Business Model and Technology Integration

Take Solutions' entry strategy centers on a dual model combining product innovation with technology-enabled health solutions. The company plans to develop science-backed nutraceuticals, biohacking-focused products, and predictive digital tools for tracking metabolic health, sleep, cognition, and biological aging.

"Through this initiative, we aim to build a diversified revenue mix across consumer products, services, and digital platforms, while leveraging our core strengths in healthcare and regulatory execution to deliver solutions that are both scalable and clinically credible," said Mr. Parmeshvar Dhangare, Director of Take Solutions Limited.

Competitive Positioning and Market Strategy

The company believes its existing capabilities in healthcare operations, regulatory support, and life sciences can be extended to accelerate development, validation, and commercialization in the longevity market. This approach aims to create differentiated offerings in an underpenetrated market with strong repeat-purchase potential and attractive margin profiles, supported by rising consumer awareness and increasing lifestyle disease burden in India.

Historical Stock Returns for Take Solutions

1 Day5 Days1 Month6 Months1 Year5 Years
-4.97%-26.43%-41.90%-1.89%+234.66%-55.98%

How will Take Solutions differentiate its longevity products from established players like Himalaya and Patanjali in India's competitive nutraceuticals market?

What regulatory hurdles might the company face when launching biohacking solutions in India, given the evolving FSSAI guidelines for health supplements?

Could this strategic pivot impact Take Solutions' existing clinical research and IT services business, and how will resources be allocated between segments?

More News on Take Solutions

1 Year Returns:+234.66%